| 1.67 -0.04 (-2.34%) | 04-23 11:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.58 | 1-year : | 3.02 |
| Resists | First : | 2.21 | Second : | 2.58 |
| Pivot price | 1.87  |
|||
| Supports | First : | 1.6 | Second : | 1.33 |
| MAs | MA(5) : | 1.65 |
MA(20) : | 1.96 |
| MA(100) : | 1.91  |
MA(250) : | 1.89 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.8 |
D(3) : | 7.1 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 3.78 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LXRX ] has closed above bottom band by 22.8%. Bollinger Bands are 6.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.66 - 1.67 | 1.67 - 1.67 |
| Close: | 1.7 - 1.71 | 1.71 - 1.72 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Tue, 23 Apr 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Hold Rating from Needham & Company LLC - MarketBeat
Mon, 22 Apr 2024
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers - Seeking Alpha
Wed, 13 Mar 2024
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin - Yahoo Finance
Mon, 11 Mar 2024
Lexicon Pharmaceuticals Launches Strategic Private Placement - TipRanks.com - TipRanks
Mon, 11 Mar 2024
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Sun, 18 Feb 2024
Insiders Of Lexicon Pharmaceuticals Reap Rewards After Their Investment Jumps Another US$2.8m - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -95 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.4624e+008 (%) |
| Held by Institutions | 1.0003e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.81 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 657.6 % |
| Return on Equity (ttm) | -50.7 % |
| Qtrly Rev. Growth | 1.2e+006 % |
| Gross Profit (p.s.) | 246.4 |
| Sales Per Share | -87 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.712e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | -0.1 |
| Price to Book value | -2.1 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0 |
| Dividend | 2.191e+007 |
| Forward Dividend | 2.107e+007 |
| Dividend Yield | 1304170000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|